Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Lucerastat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lucerastat's Registration Path Positions It As Potential First
    Lucerastat's Registration Path Positions It As Potential First

    06 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/06/3233573/0/en/Clear-route-to-registration-positions-lucerastat-as-the-potential-first-oral-therapy-for-all-patients-with-Fabry-disease.html

    GLOBENEWSWIRE
    06 Feb 2026
    Share Share
    Idorsia To Present Lucerastat Data At Worldsymposium
    Idorsia To Present Lucerastat Data At Worldsymposium

    30 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/30/3229223/0/en/Idorsia-to-present-long-term-lucerastat-data-and-kidney-biopsy-results-at-WORLDSymposium.html

    GLOBENEWSWIRE
    30 Jan 2026
    Share Share
    Idorsi's Fabry drug fails to relieve pain in phase 3 test
    Idorsi's Fabry drug fails to relieve pain in phase 3 test

    12 Oct 2021

    // Max Gelman ENDPTS

    https://endpts.com/idorsias-fabry-disease-program-flops-a-phiii-study-leaving-its-future-unclear/

    Max Gelman ENDPTS
    12 Oct 2021
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.